Pre-surgery targeted therapy for advanced thyroid cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests whether giving targeted drugs before surgery can shrink advanced thyroid cancers that are hard to remove. It uses genetic test results to match you to a specific treatment arm, aiming to make surgery safer and more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of thyroid cancer that cannot be treated with standard surgery alone—like radioactive-iodine-refractory, medullary, anaplastic, or another advanced thyroid cancer.
- A team of thyroid experts has said your cancer cannot be removed fully by surgery, or surgery would be too risky.
- Your cancer has a specific genetic change (like BRAF, RET, NTRK, TERT, or others) or shows signs that a certain targeted drug might help (like PD-L1 positivity or prior progression on multi-kinase inhibitors).
- You are in fairly good health overall (able to care for yourself and be up and about at least half the day).
- You have at least one tumor that can be measured on scans (or for medullary thyroid cancer, abnormal blood markers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving treatment before surgery (neoadjuvant therapy) helps people with locally advanced thyroid cancer. It aims to shrink the tumor so surgery can be more successful.
This study looks at how different genetic types of advanced thyroid cancer respond to treatment in real-world settings. It may help doctors choose the best therapy for you based on your tumor’s genetic makeup.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This trial tests a combination of two drugs (sinibolimab and lenvatinib) given before surgery. The goal is to shrink advanced thyroid cancer that cannot be fully removed otherwise, so that surgery can be more successful.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
This trial tests a combination of two drugs—donafenib (a targeted therapy) and an immunotherapy (anti-PD-1 antibody)—given before surgery for locally advanced differentiated thyroid cancer. The goal is to shrink the tumor to make surgery easier and more complete. If you have this type of thyroid cancer that is hard to remove completely with surgery alone, this study may be an option.
Hear when a new Thyroid Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.